Company intelligence / Profile preview
Nanogenics
Selkirk, Scotland, United Kingdomnanogenics.co.uk ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing gene therapy solutions including ECP-102 for cancer treatment and ECP-105 for glaucoma treatment. Currently seeking pre-IND approval for ECP105 and awaiting orphan designation status.
- Therapeutic areas
- OncologyOphthalmologyGastroenterology
- Modalities
- RNA therapeuticsGene therapyGene silencingGene-enhancing medicines
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
N4 PharmaSRI International IncUniversity of Queensland
Beyond the preview
Go deeper on Nanogenics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanogenics.